SWOG LUNGMAP – S1900G

A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

For more information about this clinical trial, click here

Schema & Eligibility SWOG S1900G – LUNG-MAP Sub-study

Available at:

CoxHealth Medical Center, Springfield, MO
Mercy Hospital, Springfield, MO
Delbert Day Cancer Institute at PCRMC, Rolla, MO
Freeman Health System, Joplin, MO
Good Samaritan Regional Health Center, Mt. Vernon, IL
Saint Mary’s Hospital, Centralia, IL
OSF Saint Anthony Health Center, Alton, IL
Mercy Hospital, St. Louis, MO
Mercy South, St. Louis, MO
Mercy Hospital, Oklahoma City, OK
Mercy Hospital, Fort Smith, AK
Mercy Hospital, Joplin, MO
Mercy Clinic Cancer & Hematology, Rolla, MO
Mosaic Life Care, St. Joseph, MO
Central Care Cancer Center, Bolivar, MO
Central Care Cancer Center, Great Bend, KS
Central Care Cancer Center, Garden City, KS

Ask your physician about participating in this clinical trial or call us.